Targeted Oncology

Choosing Chemotherapy With or Without Immunotherapy and the Use of PD-1 Inhibitors in ESCC

This discussion examines the key considerations oncologists weigh when choosing between chemotherapy alone or chemotherapy ...

Compounding Chemotherapy Market to Reach $6.3 Billion by 2027 in the short run and $9.8 Billion by 2034 Globally, at 6.4% CAGR: Allied Market Research

Compounding Chemotherapy Market to Reach $6.3 Billion by 2027 in the short run and $9.8 Billion by 2034 Globally, at 6.4% CAGR: Allied Market Research ...
Health Affairs

Follow-On Cancer Drugs Target Earlier Stages Than Initial Drugs: Implications Of The IRA

The Inflation Reduction Act (IRA) of 2022 mandates price negotiations for certain drugs under Medicare, shortening the exclusivity period historically used to recoup research and development ...

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology ...

The Brisbane Cancer Conference is a premier oncology meeting that brings together leading international researchers, clinicians and industry experts working in the fields of translational oncology, ...